{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:19Z","timestamp":1791492679480,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semarthrit.2026.152917","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:20:30Z","timestamp":1768234830000},"page":"152917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-5248","authenticated-orcid":false,"given":"S.A.","family":"Bergstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Niemantsverdriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.M.","family":"van der Helm-van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semarthrit.2026.152917_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.152917_bib0002","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/rheumatology\/kex236","article-title":"Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy","volume":"56","author":"Bergstra","year":"2017","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/rir-2020-0008","article-title":"Biomarkers for treatment response in rheumatoid arthritis: where are they?","volume":"1","author":"Zhao","year":"2020","journal-title":"Rheumatol Immunol Res"},{"issue":"66","key":"10.1016\/j.semarthrit.2026.152917_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22660","article-title":"Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews","volume":"22","author":"Archer","year":"2018","journal-title":"Health Technol Assess"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.152917_bib0005","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/acr.20188","article-title":"Predictors for remission in rheumatoid arthritis patients: a systematic review","volume":"62","author":"Katchamart","year":"2010","journal-title":"Arthritis Care Res (Hob)"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152917_bib0006","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3899\/jrheum.141586","article-title":"Prediction of remission in a french early arthritis cohort by RAPID3 and other core data set measures, but not by the absence of rheumatoid factor, anticitrullinated protein antibodies, or radiographic erosions","volume":"43","author":"Castrej\u00f3n","year":"2016","journal-title":"J rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/ard.2006.056937","article-title":"Sex: a major predictor of remission in early rheumatoid arthritis?","volume":"66","author":"Forslind","year":"2007","journal-title":"Ann rheum dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152917_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000773","article-title":"Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study","volume":"4","author":"Norvang","year":"2018","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.152917_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/acr.22932","article-title":"Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Liu","year":"2017","journal-title":"Arthritis Care Res (Hob)"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.152917_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/1756-185X.13036","article-title":"Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the predict study","volume":"20","author":"Bird","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152917_bib0011","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.semarthrit.2018.09.003","article-title":"Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? a collaborative analysis from three observational cohorts","volume":"48","author":"Baganz","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152917_bib0012","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00296-017-3833-z","article-title":"HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis","volume":"37","author":"Lee","year":"2017","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.152917_bib0013","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10067-016-3220-2","article-title":"No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study","volume":"35","author":"Kim","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152917_bib0014","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/14397595.2018.1482609","article-title":"Predictive factors for structural remission using abatacept: results from the ABROAD study","volume":"29","author":"Murakami","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152917_bib0015","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s10067-016-3246-5","article-title":"Predictors of remission, erosive disease and radiographic progression in a colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study","volume":"35","author":"Quintana-Duque","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152917_bib0016","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3899\/jrheum.140137","article-title":"Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis\u2013results from the canadian early arthritis cohort (CATCH)","volume":"41","author":"Kuriya","year":"2014","journal-title":"J rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152917_bib0017","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","article-title":"Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial","volume":"39","author":"van der Heijde","year":"2012","journal-title":"J rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.152917_bib0018","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3899\/jrheum.120736","article-title":"Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes","volume":"40","author":"Barra","year":"2013","journal-title":"J rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.152917_bib0019","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00296-011-2260-9","article-title":"The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years","volume":"32","author":"da Mota","year":"2012","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152917_bib0020","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/rheumatology\/kew285","article-title":"Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: a cross-sectional analysis of US veterans","volume":"55","author":"Sokolove","year":"2016","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0021","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13075-018-1553-8","article-title":"Does the presence of magnetic resonance imaging-detected osteitis at diagnosis with rheumatoid arthritis lower the risk for achieving disease-modifying antirheumatic drug-free sustained remission: results of a longitudinal study","volume":"20","author":"Burgers","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001525","article-title":"Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy","volume":"7","author":"Sundin","year":"2021","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann rheum dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152917_bib0024","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40744-022-00519-9","article-title":"Sustained remission and outcomes with abatacept plus methotrexate following stepwise dose de-escalation in patients with early rheumatoid arthritis","volume":"10","author":"Emery","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.152917_bib0025","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1007\/s12325-019-01020-6","article-title":"Determining MRI inflammation targets when considering a rheumatoid arthritis treat-to-target strategy: results of a randomized, placebo-controlled trial","volume":"36","author":"Ahmad","year":"2019","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152917_bib0026","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3899\/jrheum.161433","article-title":"The omeract rheumatoid arthritis magnetic resonance imaging (MRI) scoring system: updated recommendations by the OMERACT MRI in arthritis working group","volume":"44","author":"Ostergaard","year":"2017","journal-title":"J rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0027","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","article-title":"HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA","volume":"23","author":"Rigby","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","article-title":"Predicting arthritis outcomes\u2013what can be learned from the leiden early arthritis clinic?","volume":"50","author":"de Rooy","year":"2011","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.152917_bib0029","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1093\/rheumatology\/keac017","article-title":"Hand and foot MRI in contemporary undifferentiated arthritis: in which patients is MRI valuable to detect rheumatoid arthritis early?","volume":"61","author":"den Hollander","year":"2022","journal-title":"large prospect study Rheumatol (Oxf Engl)"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12874-017-0442-1","article-title":"When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC med res methodol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann intern med"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0032","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann intern med"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.152917_bib0033","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.152917_bib0034","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/annrheumdis-2018-213035","article-title":"Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors","volume":"77","author":"Teitsma","year":"2018","journal-title":"Ann rheum dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.152917_bib0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/ard.2010.139212","article-title":"Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial","volume":"70","author":"Saevarsdottir","year":"2011","journal-title":"Ann rheum dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.152917_bib0036","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/rheumatology\/kez490","article-title":"What do we measure with 28-joint DAS in elderly patients? an explorative analysis in the NOR-DMARD study","volume":"59","author":"van Onna","year":"2020","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0037","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1038\/s41598-024-56987-2","article-title":"Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis","volume":"14","author":"Cha","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0038","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s42358-024-00352-4","article-title":"Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive","volume":"64","author":"Harrold","year":"2024","journal-title":"Adv Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.152917_bib0039","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1136\/annrheumdis-2014-205208","article-title":"MRI-detected subclinical joint inflammation is associated with radiographic progression","volume":"73","author":"Krabben","year":"2014","journal-title":"Ann rheum dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.152917_bib0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13075-019-2002-z","article-title":"A search to the target tissue in which RA-specific inflammation starts: a detailed MRI study to improve identification of RA-specific features in the phase of clinically suspect arthralgia","volume":"21","author":"Matthijssen","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:41:00Z","timestamp":1791492060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"alternative-id":["S0049017226000065"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152917","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of achieving clinical remission in ACPA-positive RA-patients treated with abatacept and methotrexate and methotrexate monotherapy: a post-hoc analysis of the AVERT and AVERT-II trials","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152917"}}